Abstract
Chemoresistance is one of the major hurdles in cancer treatment leading to recurrence of cancer and affects the overall survival of patients. Cancer chemoresistance can be associated with various phenomena including modulation of vital cellular pathways. Unrevealing these alterations could provide a better understanding of chemoresistance and assist in the identification of new targets to overcome it. Recent advances in the field of proteomics and metabolomics have substantially helped in the identification of potential targets for chemoresistance in various cancers. This review highlights the potential of proteomics and metabolomics research to explore the putative targets associated with cancer chemoresistance with a special focus on Multiple Myeloma (MM). MM is a type of hematological malignancy which constitutes about 13% of all blood cell cancers. The therapeutic advancements for MM have increased the median overall survival rate to over 3-fold in the last one and half decade. Although in recent times, significant improvements in the overall survival rate of MM are achieved, MM remains an incurable disease with unpredictable refractory mechanisms. In spite of therapeutic advances, chemoresistance thrives to be a major hurdle in the treatment of multiple myeloma which demands a better understanding of chemoresistance. In this review, we have attempted to highlight the potential applications of proteomics and metabolomics research in the understanding of chemoresistance in MM.
Keywords: Cancer chemoresistance, Proteomics, Metabolomics, Multiple myeloma, Bortezomib, DNA.
Current Topics in Medicinal Chemistry
Title:Current Understanding of the Potential of Proteomics and Metabolomics Approaches in Cancer Chemoresistance: A Focus on Multiple Myeloma
Volume: 18 Issue: 30
Author(s): Venkatesh Chanukuppa, Ravindra Taware, Tathagat Chatterjee, Sanjeevan Sharma, Tushar H. More, Khushman Taunk, Saravanan Kumar, Manas K. Santra and Srikanth Rapole*
Affiliation:
- Proteomics Lab, National Centre for Cell Science, Ganeshkhind, Pune-411007, MH,India
Keywords: Cancer chemoresistance, Proteomics, Metabolomics, Multiple myeloma, Bortezomib, DNA.
Abstract: Chemoresistance is one of the major hurdles in cancer treatment leading to recurrence of cancer and affects the overall survival of patients. Cancer chemoresistance can be associated with various phenomena including modulation of vital cellular pathways. Unrevealing these alterations could provide a better understanding of chemoresistance and assist in the identification of new targets to overcome it. Recent advances in the field of proteomics and metabolomics have substantially helped in the identification of potential targets for chemoresistance in various cancers. This review highlights the potential of proteomics and metabolomics research to explore the putative targets associated with cancer chemoresistance with a special focus on Multiple Myeloma (MM). MM is a type of hematological malignancy which constitutes about 13% of all blood cell cancers. The therapeutic advancements for MM have increased the median overall survival rate to over 3-fold in the last one and half decade. Although in recent times, significant improvements in the overall survival rate of MM are achieved, MM remains an incurable disease with unpredictable refractory mechanisms. In spite of therapeutic advances, chemoresistance thrives to be a major hurdle in the treatment of multiple myeloma which demands a better understanding of chemoresistance. In this review, we have attempted to highlight the potential applications of proteomics and metabolomics research in the understanding of chemoresistance in MM.
Export Options
About this article
Cite this article as:
Chanukuppa Venkatesh , Taware Ravindra , Chatterjee Tathagat , Sharma Sanjeevan , More H. Tushar , Taunk Khushman, Kumar Saravanan , Santra K. Manas and Rapole Srikanth *, Current Understanding of the Potential of Proteomics and Metabolomics Approaches in Cancer Chemoresistance: A Focus on Multiple Myeloma, Current Topics in Medicinal Chemistry 2018; 18 (30) . https://dx.doi.org/10.2174/1568026619666181130111202
DOI https://dx.doi.org/10.2174/1568026619666181130111202 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
JAK2 as a Molecular Marker in Myeloproliferative Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry The Molecular Mechanisms of TRAIL Resistance in Cancer Cells: Help in Designing New Drugs
Current Pharmaceutical Design Thalidomide: A Banned Drug Resurged into Future Anticancer Drug
Current Drug Therapy Subject Index To Volume 3
Current Genomics The Akt Pathway: Molecular Targets for Anti-Cancer Drug Development
Current Cancer Drug Targets Histone Modifier Differentially Regulates Gene Expression and Unravels Survival Role of MicroRNA-494 in Jurkat Leukemia
MicroRNA Stem Cells and Cardiovascular Repair: A Role for Natural and Synthetic Molecules Harboring Differentiating and Paracrine Logics
Cardiovascular & Hematological Agents in Medicinal Chemistry Anti-Tumor Efficacy of Pyrvinium Pamoate Nanoliposomes in an Experimental Model of Melanoma
Anti-Cancer Agents in Medicinal Chemistry Phytochemicals as Adjunctive with Conventional Anticancer Therapies
Current Pharmaceutical Design Impact of Leukemia Stem Cells Phenotype Expression on Response to Induction Therapy in Acute Myeloid Leukemia Patients
Cardiovascular & Hematological Disorders-Drug Targets STAT Signaling and Cell Function
Current Genomics Advances in Interleukin-12 Gene Therapy for Acquired Liver Diseases
Current Gene Therapy Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma
Current Cancer Therapy Reviews Current and Emerging Therapies in Primary Myelofibrosis
Cardiovascular & Hematological Disorders-Drug Targets Ewing Sarcoma Family Tumors: Past, Present and Future Prospects
Current Cancer Therapy Reviews IL-2 Receptor Targeted Immunomodulatory Biologics: The Past, Present, and Future
Current Immunology Reviews (Discontinued) From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?
Current Cancer Drug Targets Recent Advances in Cancer Therapy: An Overview
Current Pharmaceutical Design Erlotinib: A Targeted Anticancer Drug
Current Cancer Therapy Reviews Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes
Current Pharmaceutical Design